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Abstract
There are four closely-related dengue virus (DENV) serotypes. Infection with one serotype 
generates antibodies that may cross-react and enhance infection with other serotypes in a 
secondary infection. We demonstrated that DENV serotype 2 (DENV2)–specific human 
monoclonal antibody (HMAb) 2D22 is therapeutic in a mouse model of antibody-enhanced severe 
dengue disease. We determined the cryo–electron microscopy (cryo-EM) structures of HMAb 
2D22 complexed with two different DENV2 strains. HMAb 2D22 binds across viral envelope (E) 
proteins in the dimeric structure, which probably blocks the E protein reorganization required for 
virus fusion. HMAb 2D22 “locks” two-thirds of or all dimers on the virus surface, depending on 
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PVP94/07, 37°C-2D22-PVP94/07 and BF-37°C-2D22-NGC class II were deposited in the Protein Data Bank under accession codes 
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deposited in the Electron Microscopy Database under accession numbers EMD-2967, EMD-2996, EMD-2997, EMD-2999, 





Figs. S1 to S13




Science. Author manuscript; available in PMC 2016 July 03.
Published in final edited form as:













the strain, but neutralizes these DENV2 strains with equal potency. The epitope defined by HMAb 
2D22 is a potential target for vaccines and therapeutics.
Dengue virus (DENV), consisting of four serotypes (DENV1 to 4), is a major human 
pathogen transmitted by mosquitoes (1, 2). DENV causes disease ranging from mild dengue 
fever to the severe dengue hemorrhagic fever/dengue shock syndrome. Preexisting 
antibodies against one serotype can enhance infection by virus of a second serotype. This is 
probably due to the targeting of virus complexed with non-neutralizing antibodies to 
monocytic cells via interaction with the Fcγ-receptor, thereby increasing virus infection, a 
process called antibody-dependent enhancement (ADE) of infection (3). Therefore, a safe 
dengue vaccine should elicit equivalent levels of potently neutralizing responses against all 
four serotypes. Recent phase 3 clinical trials of a tetravalent vaccine showed poor efficacy, 
especially against DENV2 (4, 5).
Previous in vitro studies showed that DENV2-specific human monoclonal antibody (HMAb 
2D22) has potent neutralization capacity (6). We showed that HMAb 2D22 protects against 
DENV2 when the antibody is administered before (Fig. 1A) or after (Fig. 1B) DENV2 
inoculation in an AG129 mouse model (supplementary text). This indicates the potential of 
using this HMAb as both a prophylactic and therapeutic agent. We also showed that 
therapeutic administration of the LALA mutant variant of HMAb 2D22 (which abolishes Fc 
receptor binding) to AG129 mice pretreated with polyclonal DENV1 serum and then 
inoculated with DENV2, prevents development of antibody-enhanced lethal vascular leak 
disease (supplementary text) (Fig. 1C).
DENV-neutralizing antibodies primarily target the viral envelope (E) protein. The E protein 
contains three domains: DI, DII, and DIII (fig. S1). The cryo–electron microscopy (cryo-
EM) structure of DENV2 at 4°C (7) showed E proteins arranged in icosahedral symmetry, 
with three individual E proteins (A, B, and C molecules) in each asymmetric unit (fig. S1). 
The E proteins exist as dimers, and three of the dimers lie parallel to each other, forming a 
raft (7, 8). The 30 rafts are arranged in a herringbone pattern on the virus surface. This 
structure represents DENV that was grown in mosquito cells (28°C) and then kept at 4°C. 
However, when exposed to 37°C, the surface proteins of three DENV2 laboratory-adapted 
strains (NGC, WHO, and 16681) undergo structural rearrangement (9, 10), resulting in 
bumpy-surfaced expanded virus particles (fig. S2). This was also observed in a mouse-
adapted DENV2 strain (fig. S2). On the other hand, the virus particles of clinical isolate 
DENV2 PVP94/07 did not undergo structural changes at 37°C (fig. S2). Thus, we solved the 
cryo-EM structures of Fab 2D22 complexed with both DENV2(PVP94/07) and 
DENV2(NGC) strains (fig. S2).
The cryo-EM structures of Fab 2D22:DENV2 (PVP94/07) at 4° and 37°C were determined 
to a resolution of 6.5 Å (Fig. 2A and figs. S3 and S4) and 7 Å (figs. S3 and S5, A and B), 
respectively. As the maps were very similar, the 4°C-2D22-PVP94/07 structure was used to 
identify the Fab-E protein interactions. There are 180 copies of the Fabs on the virus (Fig. 
2A and table S1). The Fab binds across E proteins within a dimer (Fig. 2, B and C). The 
interactions of the Fabs with each of the three dimers (A-C′, B-B′, and C-A′) in a raft vary 
slightly (Fig. 2C and table S2). Some of the Fabs also bind to the E protein inter-dimer and 
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inter-raft interface. However, these additional residues are unlikely to be important for 
antibody binding, because the studies described below show that HMAb 2D22 also binds to 
the expanded 37°C-DENV2(NGC) structure, which has an altered quaternary structure. In 
addition, increasing the contour of the 4°C-2D22-PVP94/07 cryo-EM density map showed 
that the three individual Fab molecule densities in an asymmetric unit are equally strong 
(fig. S6). This suggests that the interaction of a Fab with an E protein dimer, which is 
common between these Fabs in the asymmetric unit, is sufficient for binding.
The light chain of Fab 2D22 bound to DIII and the glycan loop on DI of one E protein, 
whereas the heavy chain bound to DII, including the fusion loop, of another (Fig. 2C, fig. 
S7, and table S2). The Fab also caused the glycan-containing loop on DI on an E protein to 
change in position (Fig. 2D and fig. S4D). Examination of the possible binding of two arms 
of an immunoglobulin G (IgG) molecule to the DENV virion surface showed that they could 
bind to adjacent E protein dimers but not to those farther apart (fig. S8).
Previous studies showed that the DENV2 NGC strain can change in structure at 37°C (fig. 
S2) (9), suggesting that antibody binding may be affected. We solved the structure of the 
2D22-NGC DENV2 complex at 4° and 37°C. The 4°C cryo-EM structure of the NGC-2D22 
complex (fig. S9A and table S1) was similar to the structure of the Fab 2D22: 
DENV2(PVP94/07) complex (Fig. 2A and fig. S5A).
There are two possible scenarios for how this antibody could bind to DENV2 (NGC) when 
infecting humans: It may bind to the virus before and/or after it has changed in structure at 
37°C. Therefore, we examined the virus-Fab complex structures when the antibody was 
added before (BF-37°C-2D22-NGC) or after (AF-37°C-2D22-NGC) shifting the 
temperature to 37°C. In both BF-37°C-2D22-NGC and AF-37°C-2D22-NGC samples, two 
classes of particles (class I and II) were observed. All class I structures were similar to the 
Fab complexed to the unexpanded virus structure (fig. S9, B and C). Therefore, only class II 
structures will be described.
The class II BF-37°C-2D22-NGC structure (20 Å resolution, fig. S10) showed 120 Fab 
molecules on the virus surface (Fig. 3A, fig. S11, and table S1), with all E protein dimers on 
a higher radius as compared to the unexpanded 4°C control complex structure (Fig. 3B, i). 
Fab molecules remained bound to all A-C dimers, whereas those on the B-B′ dimer had 
disassociated (Fig. 3A, right). In the BF-37°C-2D22-NGC structure, the Fab that was 
previously bound to the B-B′ dimer at 4°C (fig. S9A) must have dissociated when the 
temperature was increased. Movement of the A-C dimers from their position in the 4°C 
control structure to that in the BF-37°C-2D22-NGC structure would cause clashes of these E 
proteins with the Fab that was bound to the B-B′ dimer (Fig. 3C). This steric conflict may 
“knock off” the Fab and cause the B-B′ dimer to rotate, as observed in the BF-37°C-2D22-
NGC structure. Also, as suggested by the uncomplexed stage 3 DENV2(NGC) 37°C 
structure, the B-B′ dimer may dissociate, contributing to the detachment of Fab as observed 
in the BF-37°C-2D22-NGC structure.
The class II BF-37°C-2D22-NGC structure may represent a structure trapped at an 
intermediate stage of expansion at 37°C. Previous cryo-EM studies of the uncomplexed 
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37°C DENV2(NGC) sample showed four stages of structural change (9), of which only 
stage 1 and 3 structures were interpreted. The first stage is similar to the unexpanded 
structure. The third stage showed that all dimers had moved to a higher radius. The A-C 
dimer rotated, whereas the B-B′ dimer dissociated from each other. Comparison of the class 
II BF-37°C-2D22-NGC structure with the DENV2 37°C stage 3 structure (Fig. 3B, ii) 
showed similar organization to that of the A-C dimers. The B-B′ dimer, on the other hand, 
seemed to be a transitional structure between the DENV2 NGC 37°C stage 1 and 3 structure, 
as it lay at a radius in between these two structures (Fig. 3B, i and ii).
The ~21 Å resolution class II AF-37°C-2D22-NGC cryo-EM map (Fig. 4, A and B, and fig. 
S10) showed clear Fab densities near the fivefold vertices and much weaker Fab densities 
near the threefold vertices. The E protein densities were sparse; therefore, the map was not 
interpreted. The positions of Fab density near the fivefold vertices was similar to those in the 
BF-37°C-2D22-NGCmap, but not those near the threefold vertices. The Fab densities near 
the fivefold and threefold vertices probably represent those that are bound to each end of the 
A-C′ dimer. Neutralization profiles of BF-37°C-2D22-NGC and AF-37°C-2D22-NGC 
samples were similar (fig. S12B), suggesting that the poor Fab density near the threefold 
vertices may be due to local movement in the structure rather than low Fab occupancy.
DENV fusion in endosomes requires E protein dimers to disassociate and then reassociate 
into trimeric structures. Fab 2D22 locks both ends of all dimers on DENV2(PVP94/07), 
thereby preventing E protein reorganization. In the BF-37°C-2D22-NGC and 
AF-37°C-2D22-NGC samples, only two-thirds of the dimers on the virus surface are locked. 
The remaining free dimer in each raft is probably unable to form trimers. Indeed, HMAb 
2D22 effectively neutralized DENV2 strains PVP94/07 and NGC, even though the latter 
bound one-third fewer antibody molecules (fig. S12A).
Many human antibodies that strongly neutralize dengue bind to quaternary epitopes 
(epitopes involving more than one E protein molecule) (6, 11, 12). Human antibodies that 
neutralize DENV serotypes 1 and 3 bound to quaternary epitopes, which require virion 
assembly (11, 12). In contrast, HMAb 2D22 binds to a simpler epitope that requires only the 
formation of E homodimers. Several DENV serotype cross-neutralizing human antibodies 
(13) were also shown to bind E protein dimer epitope (EDE) (fig. S13, B, C, and D). These 
EDEs are largely similar to 2D22 epitope (fig. S13, A, B and C). Compared to HMAb C8 
and C10 (fig. S13, A, B, and C), HMAb 2D22 has more interactions on DIII that are unique 
to DENV2 (fig. S13E), leading to its serotype specificity.
The DENV2 surface is more dynamic than that of the other serotypes (9, 10). Thus, 
antibodies that bind across different dimers and rafts may lose potency, depending on the 
temperature and strain of DENV2. Therefore, antibodies binding to “simpler” epitopes, such 
as monomers or dimers, may be more effective against this serotype.
In areas of high dengue endemicity, a potential therapeutic needs to be protective in the 
presence of preexisting antibodies (14). Certain MAb LALA variants protect therapeutically 
against an ADE infection, because they are neutralizing and at the same time suppress the 
enhancing potential of preexisting fusion loop antibodies by displacing their binding (15–
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17). In contrast, highly neutralizing DIII MAbs that do not block fusion loop enhancing 
antibodies protect in high-dose-DENV2-lethal, but not ADE-DENV2-lethal challenge (Fig. 
1C) (17). The increased efficacy of HMAb 2D22 may be due to its ability to lock E proteins 
and also block the binding of low-affinity fusion-loop enhancing antibodies.
The molecular features of the 2D22 epitope and the ability of HMAb 2D22-LALA to 
prevent ADE will aid in the development of vaccines and therapeutics, respectively.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Prophylactic and therapeutic efficacy of HMAb 2D22 and 2D22-LALA in DENV2-
inoculated mice
(A) Prophylactic studies. AG129 mice injected with HMAb 2D22 24 hours before sublethal 
challenge with DENV2 strain D2S10 showed significant reduction in serum viremia and 
bone marrow viral load, compared to the control mice receiving IgG1 isotype control. The 
DENV2 limit of detection (LOD) is indicated by the dashed line. Significance was 
determined using a two-tailed Wilcoxon rank-sum test (*P < 0.05). Shown is one of two 
representative experiments, with n = 4 mice per group. (B) Therapeutic efficacy after high-
dose-DENV2-lethal infection. AG129 mice were first inoculated with DENV2 D2S10, and 
then 20 µg of HMAb 2D22-LALA was administered 24 hours later. Chimeric human-mouse 
MAb E60-N297Q or IgG1 isotype controls were used to treat control animals. Shown are 
the combined results from two independent experiments, with n = 9, 8, or 4 mice for the 
IgG1, 2D22-LALA, or E60-N297Q groups, respectively. Significance was determined using 
the Mantel-Cox log-rank test (P < 0.001, 2D22-LALA versus IgG1). (C) Therapeutic 
efficacy after ADE-DENV2-lethal infection. AG129 mice were administered a lethal 
enhancing dose of anti-DENV1 serum 24 hours before inoculation with DENV2 D2S10. 
The indicated MAb was delivered intraperitoneally 24 hours after inoculation. The results 
from two independent experiments are shown, with n = 8 mice for the IgG1, 2D22-LALA 
(20 or 50 µg) and E60-N297Q (20 µg) groups, n = 4 for the group receiving 50 µg of E60-
N297Q, and n = 3 for E87-N297Q. Mice receiving 20 or 50 µg of 2D22-LALA displayed a 
significant level of protection compared to IgG1 control mice (P < 0.001, Mantel-Cox log-
rank test).
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Fig. 2. The 6.5 Å resolution cryo-EM structure of 4° C-2D22-PVP94/07
(A) The surface (left) and cross section (right) of the cryo-EM map. One icosahedral 
asymmetric unit is indicated by a white triangle. (B) Three Fab 2D22 molecules bind per 
asymmetric unit. The three individual E proteins in an asymmetric unit are labeled as 
molecules A, B, and C. The same molecules from an adjacent asymmetric unit in a raft 
structure are labeled as A′, B′, and C′. DI, DII, and DIII of E protein are colored in red, 
yellow, and blue, respectively. (C) The 2D22 epitopes on an E protein raft. The epitopes on 
molecules A, B, and C are largely similar; however, that on molecule A also has some 
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interactions with adjacent E proteins. The DI, DII, and DIII of the surrounding E proteins 
are colored in light gray, gray, and black, respectively. The residues that interact with heavy 
and light chains of the Fab are shown as violet and cyan spheres, respectively. Additional 
residues from adjacent E protein dimers that formed part of the epitope are shown as green 
spheres. The boundary of each epitope is indicated with a light blue dotted circle. (D) The 
glycan loop (residues 144 to 157) on one E protein moves away from the fusion loop of the 
opposite E protein in the dimer when Fab is bound. The E protein of the uncomplexed 
DENV2 (gray) is superimposed onto the E protein of the complexed structure.
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Fig. 3. Cryo-EM structure of BF-37°C-2D22-NGC (Class II)
(A) Cryo-EM map of BF-37°C-2D22-NGC (Class II) (left) and the fitted structure of the 
variable region of the Fab complexed with E dimers on a raft (right). The Fab 2D22 heavy 
and light chains are colored in violet and cyan, respectively. (B) (i) The E proteins of 
BF-37°C-2D22-NGC are on a higher radius than those of 4°C-2D22-NGC or DENV2(NGC) 
stage 1. (ii) The E protein arrangement of BF-37°C-2D22-NGC is more similar to that of the 
37°CDENV2(NGC) (stage 3) structure (top). The A-C′ dimer of BF-37°C-2D22-NGC is on 
a slightly higher radius, whereas the B-B′ are located lower when compared to the stage 3 
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NGC structure. (C) Postulated movement of the Fab-E protein complex from the 4°C-2D22-
NGC to the BF-37°C-2D22-NGC structures. The partial lifting and rotation of the A-C 
dimers would knock off the bound Fab on the B-B′ dimer (zoomed-in panel). This may then 
be followed by the rotation of the B-B′ dimer.
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Fig. 4. The cryo-EMmap of AF-37°C-2D22-NGC
(A) Surface of the cryo-EM map and (B) its central cross section. Fabs bound near the five- 
and threefold vertices are indicated by black and white arrows, respectively.
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